In breast cancer, targeting WEE1 with AZD1775 has been recently investigated by others as a promising strategy in combination therapeutic approaches in different subtypes of the disease, particularly in preclinical models of TNBC (28, 30, 58–60). Here, WEE1 is linked to breast cancer.